• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl Health

Fractyl Health announces layoffs as it pivots to gene therapy

February 3, 2025 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health (Nasdaq:GUTS) is cutting nearly a fifth of its workforce as it streamlines resources and shifts focus toward certain therapies. The company, which develops therapies and procedures for treating obesity and type 2 diabetes, said it plans to prioritize its REMAIN-1 pivotal study. This study addresses the demand for an off-ramp to GLP-1 therapies. […]

Filed Under: Business/Financial News, Diabetes, Featured, Pharmaceuticals Tagged With: Fractyl Health

Fractyl Health goes the IPO route

February 2, 2024 By Chris Newmarker

This is the logo of Fractyl Health.

Fractyl Health — developer of medtech and gene therapies to reverse diabetes and obesity — began trading on the Nasdaq today under the symbol GUTS. Lexington, Massachusetts–based Fractyl Health priced its 7,333,333 shares of common stock at $15 per share, enabling it to bring in about $110 million from the IPO. The company expected the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Initial Public Offering (IPO) Tagged With: Fractyl Health

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

June 30, 2023 By Sean Whooley

American Diabetes Association ADA 2023 Medtronic MiniMed 780G Insulet Omnipod 5 Senseonics Eversense E3 GLP-1s

As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Pediatrics, Pharmaceuticals, Surgical, Technology, Wall Street Beat Tagged With: abbott, ADA 2023, American Diabetes Association, Bigfoot Biomedical, Dexcom, Eli Lilly & Co., Fractyl Health, Insulet, Medtronic, Novo Nordisk, Senseonics, Sernova Inc, Vida Health, Virta Health

Studies back Fractyl Health diabetes reversal procedure, gene therapy

June 26, 2023 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced multiple studies supporting its programs for the reversal and treatment of diabetes. Lexington, Massachusetts-based Fractyl reported data from its Revitalize 1 pivotal study and its Rejuva program. Revitalize 1 evaluates the company’s Revita endoscopic ablation procedure to reverse diabetes. Rejuva evaluates a targeted pancreatic gene therapy. The company presented its results at […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Surgical Tagged With: ADA 2023, American Diabetes Association, Fractyl Health

Fractyl Health initiates global registry for diabetes reversal treatment

April 25, 2023 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced that it initiated its Revita Global Registry Program in Germany to study its diabetes reversal treatment. On April 20, the Ethics Committee of the University of Freiburg (Germany) granted clearance for the initiation of a registry study. The study covers the Revita system in German hospitals. Patients in the registry have inadequately […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Surgical Tagged With: Fractyl Health

Fractyl Health launches diabetes reversal treatment in Germany

February 7, 2023 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced today that it commercially launched its Revita DMR system for diabetes reversal in Germany. Revita, an endoscopic procedural therapy, remodels the duodenal lining through hydrothermal ablation. This tackles a root cause of type 2 diabetes. Revita holds CE mark approval in Europe and established reimbursement in Germany recently. Lexington, Massachusetts-based Fractyl performed […]

Filed Under: Business/Financial News, Diabetes, Surgical Tagged With: Fractyl Health

Fractyl Health ‘encouraged’ by results from diabetes reversal study

January 31, 2023 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control. Interim data came from the human clinical experience in Fractyl’s Revita-T2Di long-term, open-label cohort. Revita, a procedure that remodels the duodenal lining via hydrothermal ablation, has FDA breakthrough device designation. The FDA approved an investigational […]

Filed Under: Clinical Trials, Diabetes, Featured Tagged With: Fractyl Health

Data backs gene therapy delivery system for treating type 2 diabetes from Fractyl Health

December 5, 2022 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health today announced positive preclinical proof-of-concept data in an animal model for its gene therapy delivery platform for treating type 2 diabetes. The company, which develops the Revita diabetes reversal procedure, evaluated its Rejuva program. Rejuva, a novel device and AAV-mediated delivery platform, delivers gene therapy directly targeting the pancreas. This potentially embeds multiple […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Fractyl Health

Fractyl Health forms task force to understand root causes of type 2 diabetes

November 2, 2022 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced today that it created the Erase T2D task force to research type 2 diabetes in the hopes of “erasing” the condition. The academic-industry scientific partnership aims to advance research on the role of the gut in metabolic disease. This, in turn, could catalyze future discoveries on understanding and erasing type 2 diabetes. […]

Filed Under: Business/Financial News, Diabetes, Featured, Surgical Tagged With: Fractyl Health

FDA approves IDE trial for Fractyl Health’s diabetes reversal tech in type 2 diabetes patients

April 4, 2022 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced today that it received FDA approval for an investigational device exemption (IDE) trial of its diabetes reversal platform. Lexington, Massachusetts-based Fractyl Health will evaluate its Revita treatment in patients with type 2 diabetes whose disease is inadequately controlled despite treatment with at least two antidiabetic agents (ADAs) and who are not yet […]

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Fractyl Health

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS